Laboratório de Farmacognosia, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Asa Norte, Brasília, DF, Brazil.
Fakultät für Chemie und Biochemie, Organische Chemie II, Ruhr-Universität Bochum, Bochum, Germany.
PLoS One. 2020 Nov 6;15(11):e0241855. doi: 10.1371/journal.pone.0241855. eCollection 2020.
Leishmaniasis is a disease impacting public health worldwide due to its high incidence, morbidity and mortality. Available treatments are costly, lengthy and toxic, not to mention the problem of parasite resistance. The development of alternative treatments is warranted and natural products demonstrate promising activity. This study investigated the activity of Connarus suberosus extracts and compounds against Leishmania species. Several C. suberosus extracts were tested against L. amazonensis promastigotes. Active and inactive extracts were analyzed by UHPLC-MS and data evaluated using a metabolomics platform, revealing an unknown neoflavonoid (connarin, 3), isolated together with the pterocarpans: hemileiocarpin (1) and leiocarpin (2). The aforementioned compounds (1-3), together with the benzoquinones: rapanone (4), embelin (5) and suberonone (6) previously isolated by our group from the same species, were tested against: (i) L. amazonensis and L. infantum promastigotes, and (ii) L. amazonensis intracellular amastigotes, with the most active compound (3) also tested against L. infantum amastigotes. Cytotoxicity against murine peritoneal macrophages was also investigated. Compounds 2 and 3 presented an IC50 33.8 μM and 11.4 μM for L. amazonensis promastigotes; and 44.3 μM and 13.3 μM for L. infantum promastigotes, respectively. For L. amazonensis amastigotes, the IC50 of 2 was 20.4 μM with a selectivity index (SI) of 5.7, while the IC50 of 3 was 2.9 μM with an SI of 6.3. For L. infantum amastigotes, the IC50 of 3 was 7.7 μM. Compounds 2 and 3 presented activity comparable with the miltefosine positive control, with compound 3 found to be 2-4 times more active than the positive control, depending on the Leishmania species and form. The extracts and isolated compounds showed moderate toxicity against macrophages. Compounds 2 and 3 altered the mitochondrial membrane potential (ΔΨm) and neutral lipid body accumulation, while 2 also impacted plasma membrane permeabilization, culminating in cellular disorder and parasite death. Transmission electron microscopy of L. amazonensis promastigotes treated with compound 3 confirmed the presence of lipid bodies. Leiocarpin (2) and connarin (3) demonstrated antileishmanial activity. This study provides knowledge of natural products with antileishmanial activity, paving the way for prototype development to fight this neglected tropical disease.
利什曼病是一种全球性的公共卫生疾病,其发病率、发病率和死亡率都很高。现有的治疗方法既昂贵又耗时,而且毒性大,更不用说寄生虫耐药性的问题了。有必要开发替代疗法,天然产物显示出有希望的活性。本研究调查了 Connarus suberosus 提取物和化合物对利什曼原虫的活性。几种 C. suberosus 提取物对 L. amazonensis 前鞭毛体进行了测试。活性和非活性提取物通过 UHPLC-MS 进行分析,使用代谢组学平台对数据进行评估,揭示了一种未知的新黄酮类化合物(connarin,3),与我们之前从同一种属中分离出的 pterocarpans:hemileiocarpin(1)和 leiocarpin(2)一起分离出来。上述化合物(1-3)与本课题组之前从同一种属中分离得到的苯醌:rapanone(4)、embelin(5)和 suberonone(6)一起对以下方面进行了测试:(i)L. amazonensis 和 L. infantum 前鞭毛体,以及(ii)L. amazonensis 细胞内无鞭毛体,最有效的化合物(3)也对 L. infantum 无鞭毛体进行了测试。还研究了对鼠腹腔巨噬细胞的细胞毒性。化合物 2 和 3 对 L. amazonensis 前鞭毛体的 IC50 分别为 33.8 μM 和 11.4 μM;对 L. infantum 前鞭毛体的 IC50 分别为 44.3 μM 和 13.3 μM。对于 L. amazonensis 无鞭毛体,化合物 2 的 IC50 为 20.4 μM,选择性指数(SI)为 5.7,而化合物 3 的 IC50 为 2.9 μM,SI 为 6.3。对于 L. infantum 无鞭毛体,化合物 3 的 IC50 为 7.7 μM。化合物 2 和 3 的活性与米替福新阳性对照相当,化合物 3 的活性比阳性对照高 2-4 倍,具体取决于利什曼原虫的种类和形式。提取物和分离得到的化合物对巨噬细胞表现出中等毒性。化合物 2 和 3 改变了线粒体膜电位(ΔΨm)和中性脂滴的积累,而 2 还影响了质膜的通透性,导致细胞紊乱和寄生虫死亡。用化合物 3 处理的 L. amazonensis 前鞭毛体的透射电子显微镜证实了脂滴的存在。leiocarpin(2)和 connarin(3)表现出抗利什曼原虫活性。本研究提供了具有抗利什曼原虫活性的天然产物知识,为开发对抗这种被忽视的热带病的原型奠定了基础。